A randomized double-blind placebo-controlled 8-week clinical trial to evaluate PD10(extracts of grape leaves: a kind of health supplements)'s safety and effectiveness on inhibitions of platelet aggregation

A randomized double-blind placebo-controlled 8-week clinical trial to evaluate PD10(extracts of grape leaves)'s safety and effectiveness on inhibitions of platelet aggregation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001303

Enrollment

Registered

2014-12-09

Start date

2014-05-30

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : control group take placebo. intervention group take 250mg of PD10 once per day during 8 weeks.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) over 19 years old male smoker who smokes more than 9 cigarettes per day. 2) man who have platelet aggregation power equal to and more than 70% 3) man who agree to participate this study

Exclusion criteria

Exclusion criteria: 1)Patients who have serious disease such as myocardial infarction, angina, uncontrolled hypertension, diabetes melitus, and thyroid disease 2)Man who are taking anti-platelet agents or antithrombotic agents 3)Man who had taken supplements regarding to blood circulations within 2 weeks. 4)Man who started to take lipid-lowering drug within 3 months 5)Man who have serious abnormal Lab findings, past history of major surgery, and who are participating in other research.

Design outcomes

Primary

Measure	Time frame
Power of platelet aggregation	—

Secondary

Measure	Time frame
Thromboxane B2 / Lipid profile	—

Countries

Korea, Republic of

Contacts

Public ContactKumju Shin

Asan Medical Center

Outcome results